Sheen YH, et al. - Researchers determined the impact of asthma status on the 23-valent serotype-specific pneumococcal antibody response. They performed a comprehensive medical record review of an existing vaccine cohort and retrospectively determined asthma status using the Predetermined Asthma Criteria. In association with asthma status, differences in antibody titers between pre- and post-vaccination with 23-valent pneumococcal polysaccharide vaccine (PPSV-23) were assessed. Baseline measurements of 23 serotype-specific pneumococcal antibody titers and measurements obtained at 4–6 weeks post-vaccination were evaluated. For each of the serotypes, they estimated vaccine responses to PPSV-23 from pre- to post-vaccine titers. Asthma was detected in 18 (28%) of 64 eligible and enrolled subjects. Asthmatics vs controls were more likely to exhibit poorer humoral immune responses to PPSV-23 as measured by fold change.